Angelino N, Bernacki R, Sharma M, Dodson-Simmons O, Korytnyk W. Versatile intermediates in the selective modification of the amino function of 2-amino-2-deoxy-D-mannopyranose and the 3-position of n-acetylmannosamine: potential membrane modifiers in neoplastic control., Carbohydrate Res., 276(1):99-115 1995

Bellnier DA, Potter WR, Vaughan LA, Sitnik TM, Parsons JC, Greco WR, Whitaker J, Johnson P, Henderson BW. The validation of a new vascular damage assay for photodynamic therapy agents. Photochem. Photobiol., 62(5):896-905, 1995

Bergeron RJ, McManis JS, Weimar WR, Schreier KM, Gao F, Wu Q, Ortiz-Ocasio J, Luchetta GR, Porter CW, Vinson JRT. The role of charge in polyamine analogue recognition. J. Med. Chem, 38:2278-2285, 1995

Bernacki RJ, Oberman EJ, Seweryniak K, Atwood A, Bergeron RJ, Porter CW. Preclinical antitumor efficacy with the polyamine analog, N1,N11-diethylnorspermine administered by multiple injection or continuous infusion. Clinical Cancer Res., 1:847-857, 1995

Bergeron RJ, Weimar WR, Luchetta G, Streiff RR, Wiegand J, Perrin J, Schreier KM, Porter CW, Yao GW, Dimova H. Metabolism and pharmacokinetics of N1,N11-diethylnor-spermine Drug Metab. Dispos., 23(10):1117-1125,1995

Box H, Freund H, Budzinski E, Wallace J, Maccubbin A. Free radical-induced double base lesions. Radiat. Res. 141:91-94, 1995

Cao S, Baccanari DP, Joyner S, Davis S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res., 55(24):6227-6230, 1995

Cao S, Frank C, Shirasaka T, Rustum YM. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clinical Cancer Research 1:839-845, 1995

Christman JK, Sheikhnejad G, Marasco C, Sufrin JR. 5-Methly-2’-deoxycytidine in single stranded DNA can act in cis to signal de novo DNA methylation. Proc. Natl. Acad. Sci., USA, 92:7347-7351, 1995

Cobuzzi R, Kotsopolous S, Otani T, Beerman TA. Effects of the enediyne C-1027 on DNA targets in vitro and in vivo. Biochemistry, 34:583-592, 1995

Darcy K, Shoemaker S, Lee PP, Ganis B, Ip MM. Hydrocortisone and progesterone regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture. J. Cell. Physiol., 163:365-379, 1995

Darcy K, Shoemaker S, Lee PP, Vaughan M, Black JD, Ip MM. Prolactin and epidermal growth factor regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture. J. Cellular Physiol.,163:346-364, 1995

D’Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K, Christiansen N, Frankel S, Rustum YM, Papa G, Mandelli F, Bonmassar E. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA-alkyltransferase levels: Studies with blasts of leukaemic patients. Annals of Oncology, 6:389-393, 1995

Ehrke MJ, Verstovsek S, Krawczyk CM, Ujhazy P, Zaleskis G, Maccubbin D, Mihich E. Cyclophosphamide plus tumor necrosis factor-* chemoimmunotherapy cured mice: Life-long immunity and rejection of reimplanted primary lymphoma. Intl. J. Cancer, 63(3):463-471, 1995

Felschow D, MacDiarmid J, Bardos T, Wu R, Woster P, Porter CW. Photoaffinity labeling of a cell surface polyamine binding protein. J. Biol. Chem., 270:28705-28711, 1995

Gangjee A, Devraj R, McGuire JJ, Kisliuk RL. Effect of bridge variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines. J.Med. Chem., 38(19):3798-3805, 1995

Gangjee A, Devraj R, McGuire JJ, Kisliuk RL. 5-Arylthio substituted 2-amino-4-oxo-6-methylpyrrolo[2,3-d]pyrimidine antifolates as thymidylate synthase inhibitors and antitumor agents. J. Med. Chem., 38:4495-4502, 1995

Gangjee A, Mavandadi, Queener SF, McGuire JJ. Novel 2,4-Diamino-5-Substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases. J. Med. Chem. 38:2158-2165, 1995

Han KA, Kulesz-Martin MF. Differentiation-associated expression of endogenous retrovirus-like sequence VL30 in normal mouse skin vs. squamous cell carcinomas. Mol. and Cell. Differentiation, 3:125-136, 1995

Klaich G, Kanter PM. Characterization of a monoclonal antibody recognizing a 138 kDa glioblastoma associated antigen. Anticancer Drugs 6:44-52, 1995

Kramer DL, Mett H, Regenass U, Diegelman P, Porter CW. Stable amplification of the S-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells. J. Biol. Chem., 270:2124-2132, 1995

Kramer DL, Stanek J, Diegelman P, Regenass U, Schneider, Porter CW. Use of 4-fluoro-L-ornithine to monitor metabolic flux through the polyamine biosynthetic pathway. Biochem. Pharm., 50:1433-1443, 1995

Krawczyk C, Verstovsek S, Ujhazy P, Maccubbin D, Ehrke MJ. Protective specific immunity induced by cyclophosphamide plus TNF-a combination treatment of EL4 lymphoma-bearing C57BL/6 Mice. Cancer Immunology and Immunotherapy, 40(6): 347-357, 1995

Kulesz-Martin M, Lisafeld B, Patterson J, Driscoll D, Shudo K, Roop DR, Kisiel N. Differentiation and tumor response to retinobenzoic acid RE-80 In A Malignant Conversion Model. Cancer Detection and Prevention 19:355-366, 1995

Lee PPH, Darcy KM, Shudo K, Ip MM. Interaction of retinoids with steroid and peptide hormones in modulating morphological and functional differentiation of normal rat mammary epithelial cells. Endocrinology 136:1718-1730, 1995

Lee PPH, Lee MT, Darcy KM, Shudo K, Ip MM. Modulation of normal mammary epithelial cell proliferation, morphogenesis and functional differentiation by retinoids: A comparison of the retinobenzoic acid derivative RE80 with retinoic acid. Endocrinology, 136:1707-1717, 1995

Libby PR, Munson BR, Fiel RJ, Porter CW. Cationic porphyrin derivatives as inhibitors of the enzymes of polyamine catabolism. Biochem. Pharm., 50:1527-1530, 1995

Lu K, Yin MB, McGuire J, Bonmassar E, Rustum YM. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-Glutamic Acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem. Pharmacology, 50(3):391-398, 1995

Maccubbin AE, Przybyszewski J, Evans MS, Budzinski EE, Patrzyc HB, Kulesz-Martin M, Box HC. DNA damage in UVB-irradiated keratinocytes. Carcinogenesis;16:1659-1660, 1995

Margolis MJ, Pajovic S, Wong EL, Wade M, Jupp R, Nelson JA, Azizkhan JC. Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription. J.Virol., 69:7759-7767, 1995

Markowitz S, Hines J, Lutterbaugh J, Myeroff L, Mackay W, Gordon N, Rustum YM, Luna E, Kleinerman J. Mutant K-ras oncogenes in colon cancers do not predict patient’s chemotherapy response or survival. Clinical Cancer Research,1:441-445, 1995

McGuire JJ, Hart BP, Haile WH, Rhee MS, Galivan J, Coward JK. DL-b,b-Difluoroglutamic acid mediates position-dependent enhancement or termination of pteroylpoly(*-glutamylate) synthesis catalyzed by folylpolyglutamate synthetase. Arch. Biochem. Biophys., 321:319-328, 1995

McHugh MM, Woynarowski JM, Gawron LS, Otani T, Beerman TA. The effects of the DNA damaging enediyne C-1027 on intracellular SV40 and genomic DNA in green monkey kidney BSC-1 cells. Biochemistry 34:1805-1814, 1995

Meropol NJ, Petrelli NJ, RustumYM, Rodriquez-Bigas M, Blumenson LE, Frank C, Berghorn E, Creaven PJ. A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patients with colorectal carcinoma. Invest. New Drugs, 13(2):149-155, 1995

Mihich E, Metcalf D. Meeting Report:: Normal and malignant hematopoiesis--new advances (Sixth Annual Pezcoller Symposium). Cancer Res. 55:3462-3466, 1995

Mihich E, Metcalf D. eds.,: Normal and Malignant Hematopoiesis--New Advances (Sixth Annual Pezcoller Symposium), Plenum Press, NY 1995

Moesta KT, Greco WR, Nurse-Finlay SO, Parsons JC, Mang TS. Lack of reciprocity in drug and light dose dependence of photodynamic therapy of pancreatic adenocarcinoma in vitro, Cancer Res., 55(14):3078-3084, 1995

Mudipalli A, Nadadur SS, Maccubbin AE, Gurtoo HL. Mutations induced by dacarbazine activated with cytochrome P-450. Mutation Res., 327:113-120, 1995

Ojima I, Park YH, Fenoglio I, Duclos O, Sun CM, Kuduk SD, Zucco M, Appendino G, Pera P, Veith JM, Bernacki RJ, Bissery MC, Combeau P, Vrignaud P, Riou JF Lavelle F. Syntheses and structure-activity relationships of new taxoids. IN: Taxane Anticancer Agents: Basic Science and the Current Status. Georg, G.I., Chen, T.T., Ojima, I., Vyas, D.M., (eds.); ACS Symp. Series 583, American Chemical Society, Washington, D.C., Chapter 19, pp. 262-275, 1995

Panadero A, Yin MB, Voight W, Rustum YM. Contrasting patterns of DNA fragmentation induced by Thymidylate Synthase (TS) inhibitors, ZD1694 and AG-331. Oncol. Res., 7(2):73-81, 1995

Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki R, Creaven P. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Letters, 97(2):177-184, 1995

Riva C, El-Khyari S, Rustum YM, Barra Y. Resistance to cytosine arabinoside in cells transfected with activated Ha-ras Oncogene. Anticancer Res., 15(4):1297-1302 1995

Rowan BG, Ip MM. Charge heterogeneity in wild type and variant glucocorticoid receptors in the mouse P1798 lymphosarcoma. Molec. Cellul. Endocrinol. 107:41-54, 1995

Rowan BG, Ip MM. Identification and localization of steroid-binding and non steroid-binding forms of the glucocorticoid receptor in the mouse P1798 lymphosarcoma. J. Steroid Biochem. Molec. Biol, 52:437-450, 1995

Rustum YM, Cao S. Biochemical and molecular basis of fluoropyrimidine modulation. Proc. Symposium on New Drugs - International Course of Advances in Oncology, Madrid, Spain 2/94. Chapter 1, p. 17-25, 1995

Schneider BL, Kulesz-Martin MF, Bowden GT. Induced terminal differentiation and tumorigenic supression in murine keratinocyte somatic cell hybrids. Molecular Carcinogenesis 13:6-14, 1995

Schober C, Yin MB, Gibbs J, Rustum, YM. Heterogeneity in DNA damage and repair of human ovarian tumour cells treated with Doxorubicin. Cellular Pharm. 2:177-181, 1995

Sharma A, Straubinger R, Ojima I, Bernacki R. Antitumor Efficacy of Taxane Liposomes on a Human Ovarian Tumor Xenograft in Nude Athymic Mice. J. Pharmaceutical Sciences, 84:1400-1404, 1995

Sharma M, Jain R, Ionescu E, Slocum HK. Capillary electrophoretic separation and laser-induced fluorescence detection of the major DNA adducts of cisplatin and carboplatin, Anal. Biochem., 228:307-311, 1995

Sharma M, Li Y, Ledvina M, Bobek M. Synthesis of 5’-fluoro-5’-deoxy-and 5’-amino-5’-deoxytoyocamycin and sangivamycin and some related derivatives. Nucleosides & Nucleotides, 14:1831-1852, 1995

Spector T, Cao S, Rustum Y, Harrington J, Porter D. Attenuation of the antitumor activity of 5-fluorouracil. Cancer Research 55:1239-1241, 1995

Spellman JE, Kulesz-Martin MF, Blumenson L, Beckett MA, Weichselbaum RR. Clonal interactions in human squamous cell carcinoma. J. Surgical Res. 58:165-174, 1995

Sufrin JR, Meshnick SR, Spiess AJ, Garofalo-Hannan Pan XQ, Bacchi CJ. Methionine Recycling and Antimalarial Drug Design. Antimicrobial Agents and Chemotherapy, 39:2511-2515, 1995

Sufrin JR, Spiess AJ, Marasco J, Croft SL, Snowdon D, Yardley V, Bacchi CJ. Purine 2’,3’-Acyclonucleosides: improved synthesis and antiparasitic activity. Bioorganic and Medicinal Chemistry Letters, 5:1961-1964, 1995

Van der Wilt CL, Van Laar JAM, Smid K, Rustum YM, Peters GJ. Comparison of 5-fluoro-2’-deoxyuridine and 5-fluorouracil in the treatment of murine colon cancer; effects on thymidylate synthase. In: Advances in Experimental Medicine & Biology (Proc. EORTC Mtg., The Netherlands, Mar.15-18, 1994), A. Shota and M. Taylor, eds., 370 PT 1:109-114, 1995

Vanhoefer U, Minderman H, Toth K, Scheper RJ, Slovak ML, Rustum YM. PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts overexpressing the multidrug resistance protein (MRP). Clin. Cancer Res., (In press)

VanLaar JAM, Mayhew EG, Cao S, Durrani FA, Peters GJ, Rustum YM. Modulation of the antitumor activity of cis-platin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma No. 26. Europ. J. Cancer 31:974-976, 1995

Verstovsek S, Eppolito C, Ujhazy P, Maccubbin DL, Ehrke MJ, Mihich E. Murine splenic macrophage tumoricidal activation by Cytokines. Exp. Hematology.23:519-528, 1995

Wade M, Blake MC, Jambou RC, Helin K, Harlow E, Azizkhan JC. An inverted repeat motif stabilizes binding of E2F and enhances transcription of the dihydrofolate reductase gene. J. Biol. Chem. 270:9783-9791, 1995

Watanabe S, Kavai I, Bobek M. Cyano Sugars: Synthesis by opening of an epoxide ring in pentofuranosides with diethylaluminum cyanide. J. Carbohydrates & Chem, 14:685-701, 1995

Woynarowski JM, McHugh M, Gawron LS, Beerman TA. Effects of Bizelesin (U-77779), a bifunctional akylating minor groove agent, on genomic and Simian Virus 40 DNA. Biochemistry 34:13042-13050, 1995

Yin MB, Arredondo MA, Guimaraes MA, Schober C, Rustum YM. Modulation of the in vitro cytotoxicity of doxorubicin in multidrug resistant cells with and without P-glycoprotein expression. J. Cellular Pharm., 2:23-28, 1995

Zaleskis G, Verstovsek S, Tzai TS, Mihich E, Ehrke MJ. Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol. Res. 7:307-315, 1995